

Endicott David J.  
Form 3  
October 11, 2011

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|   |         |                                      |   |  |
|---|---------|--------------------------------------|---|--|
| 1. Name and Address of Reporting Person * |         | 2. Date of Event Requiring Statement | 3. Issuer Name <b>and</b> Ticker or Trading Symbol  |  |
| Â Endicott David J.                       |         | (Month/Day/Year)                     | ALLERGAN INC [AGN]  |  |
| (Last)                                    | (First) | (Middle)                             | 4. Relationship of Reporting Person(s) to Issuer  | 5. If Amendment, Date Original Filed(Month/Day/Year) |
|   |         | 10/01/2011                           |   |  |
| 2525 DUPONT DRIVE                         |         |                                      | (Check all applicable)  |  |
| (Street)                                  |         |                                      | <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner<br><input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other<br>(give title below)    (specify below) |  |
| IRVINE,Â CAÂ 92612                        |         |                                      | 6. Individual or Joint/Group Filing(Check Applicable Line)  |  |
| (City)                                    | (State) | (Zip)                                | <input checked="" type="checkbox"/> Form filed by One Reporting Person<br><input type="checkbox"/> Form filed by More than One Reporting Person   |  |
| CVP and President, AGN Med US             |         |                                      |   |  |

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common Stock                    | 20,186 <sup>(1)</sup>                                 | D  | Â   |
| Common Stock                    | 642.5057 <sup>(2)</sup>                               | I  | By 401(k) Trust                                       |
| Common Stock                    | 3,104.9626 <sup>(3)</sup>                             | I  | by ESOP Trust   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security | 4. Conversion or Exercise | 5. Ownership Form of | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|--|---------------------------|----------------------|---|
|--|--|--|---------------------------|----------------------|---|

Edgar Filing: Endicott David J. - Form 3

|                                      | Date Exercisable | Expiration Date | (Instr. 4)<br>Title | Amount or Number of Shares | Price of Derivative Security | Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |   |
|--------------------------------------|------------------|-----------------|---------------------|----------------------------|------------------------------|--|---|
| Employee Stock Option (Right to Buy) | Â (4)            | 02/14/2018      | Common Stock        | 54,500                     | \$ 64.47                     | D  | Â |
| Employee Stock Option (Right to Buy) | Â (5)            | 02/20/2019      | Common Stock        | 30,000                     | \$ 40.16                     | D  | Â |
| Employee Stock Option (Right to Buy) | Â (6)            | 02/22/2020      | Common Stock        | 37,500                     | \$ 59.13                     | D  | Â |
| Employee Stock Option (Right to Buy) | Â (7)            | 02/17/2021      | Common Stock        | 52,000                     | \$ 75.58                     | D  | Â |

## Reporting Owners

| Reporting Owner Name / Address                             | Relationships |           |                                 |       |
|--|---------------|-----------|---------------------------------|-------|
|  | Director      | 10% Owner | Officer                         | Other |
| Endicott David J.<br>2525 DUPONT DRIVE<br>IRVINE, CA 92612 | Â             | Â         | Â CVP and President, AGN Med US | Â     |

## Signatures

Matthew J. Maletta, Attorney-in-fact for David J. Endicott

10/10/2011

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 7, 577 shares of the Issuer's common stock underlying the Restricted Stock Units awarded to the reporting person.
- (2) Shares allocated to reporting person's SIP account as of reporting date.
- (3) Shares allocated to the reporting person's ESOP account as of reporting date.
- (4) The option became exercisable in four equal annual installment beginning February 14, 2009.
- (5) The option became exercisable in four equal annual installments beginning February 20, 2010. The remaining outstanding options under this award are reported in this filing.
- (6) The option became exercisable in four equal annual installments beginning February 22, 2011. The remaining outstanding options under this award are reported in this filing.
- (7) The option becomes exercisable in four equal annual installments beginning February 17, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.